Taxanes in hormone-refractory prostate cancer

被引：8

作者：

Kang, MH ^{[1
]}

Figg, WD ^{[1
]}

Dahut, W ^{[1
]}

机构：

[1] NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA

来源：

CANCER PRACTICE | 1999年 / 7卷 / 05期

关键词：

D O I：

10.1046/j.1523-5394.1999.75005.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

收藏

页码：270 / 272

页数：3

相关论文

共 20 条

[1] FRIEDLAND D, 1999, P ASCO, V18, P1237
[2] HAAS N, 1999, P ASCO, V18, P1311
[3] HUDES GR, 1995, SEMIN ONCOL, V22, P41
[4] Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
Hudes, GR
Nathan, F
Khater, C
Haas, N
Cornfield, M
Giantonio, B
Greenberg, R
Gomella, L
Litwin, S
Ross, E
Roethke, S
McAleer, C
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) : 3156 - 3163
[5] KELLY K, 1999, J UROL S, V161, P683
[6] Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma
Kreis, W
Budman, DR
Fetten, J
Gonzales, AL
Barile, B
Vinciguerra, V
[J]. ANNALS OF ONCOLOGY, 1999, 10 (01) : 33 - 38
[7] LEITNER SP, 1999, P ASCO, V18, P1331
[8] NATALE RB, 1999, P ASCO, V18, P1343
[9] NEMETH JA, 1999, J UROL S, V161, P1138
[10] Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
Petrylak, DP
Macarthur, RB
O'Connor, J
Shelton, G
Judge, T
Balog, J
Pfaff, C
Bagiella, E
Heitjan, D
Fine, R
Zuech, N
Sawczuk, I
Benson, M
Olsson, CA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 958 - 967